Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

Long-term anti-TNF therapy appears to have a similar safety profile to short-term therapy, with no significant increase in overall AE risk. These findings may offer cautious reassurance regarding extended anti-TNF use, particularly in patients with CD on infliximab.

Institutions

University of California, Los Angeles (US)

Publication Details

Journal: Digestive Diseases and Sciences
Published: 2026-03-24
DOI: https://doi.org/10.1007/s10620-026-09797-7
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

Mar 24, 2026

Digestive Diseases and Sciences

Inflammatory Bowel Disease

article

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

March 24, 2026article en

Abstract

Digestive Diseases and Sciences

University of California, Los Angeles (US)

Good health and well-being

Openalex Percentile: Top 10%

Inflammatory Bowel Disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease · Digestive Diseases and Sciences (2026) | TGRS Research Map | TGRS